3-(tert-butyl)-N,N-dimethylaniline | 62171-62-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(tert-butyl)-N,N-dimethylaniline
• 英文别名: 3-tert-Butyl-N,N-dimethylaniline
• CAS: 62171-62-4
• 化学式: C₁₂H₁₉N
• 分子量: 177.29
• InChiKey: ABCGULWDKPUFCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(tert-butyl)-N,N-dimethylaniline 在 dirhodium tetraacetate 、 caesium carbonate 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  电子供体-受体复合物用高价碘 (III) 试剂诱导稠合吲哚

  摘要：

  已经开发出一种操作简单且有效的通过 EDA 复合物实现叔胺和高价碘试剂环化的方法。以良好的收率获得了一系列[1,2-α]吲哚衍生物，其中包括一些用于合成生物活性分子的关键中间体。此外，该既定策略具有广泛的底物范围和良好的官能团耐受性。

  DOI：

  10.1021/acs.orglett.3c02009
• 作为产物：
  描述：

  、 三甲基铝 以 正己烷 、 二氯甲烷 为溶剂， 生成 3-(tert-butyl)-N,N-dimethylaniline
  参考文献：
  名称：

  Access to “Friedel–Crafts-Restricted” tert-Alkyl Aromatics by Activation/Methylation of Tertiary Benzylic Alcohols

  摘要：

  Herein we describe a two-step protocol to prepare m-tert-alkylbenzenes. The appropriate tertiary benzylic alcohols are activated with SOCl2 or concentrated HCl and then treated with trimethylaluminum, affording the desired products in 68-97% yields (22 examples). This reaction sequence is successful in the presence of a variety of functional groups, including acid-sensitive and Lewis-basic groups. In addition to t-Bu groups, 1,1-dimethylpropyl and 1-ethyl-1-methylpropyl groups can also be installed using this method.

  DOI：

  10.1021/jo202371c

文献信息

• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Diiodomethane-Mediated Generation of <i>N</i>-Aryliminium Ions and Subsequent [4 + 2] Cycloadditions with Olefins
  作者：Yu-Quan Zhao、Jun-Jie Tian、Chong-Ren Ai、Xiao-Chen Wang

  DOI：10.1021/acs.joc.9b03148

  日期：2020.2.21

  between N,N-dimethylanilines, diiodomethane, and olefins. This transformation involves initial reaction of the aniline with diiodomethane to form an iodomethylammonium salt, which undergoes fragmentation accompanied by elimination of methyl iodide to give an N-aryliminium ion, which is trapped by the olefin via [4 + 2] cycloaddition to give the final product. This method for generating N-aryliminium ions

  在此，我们报告了一种通过N，N-二甲基苯胺与二碘甲烷反应原位生成N-芳基亚胺离子的方法。我们使用该方法通过N，N-二甲基苯胺，二碘甲烷和烯烃之间的一锅三组分反应制备四氢喹啉。此转化过程涉及苯胺与二碘甲烷的初始反应，形成碘甲基铵盐，然后进行裂解并消除甲基碘，得到N-芳基亚胺离子，该烯烃经[4 + 2]环加成反应被烯烃捕获，得到最终产物。产品。这种产生N-芳基亚胺离子的方法既不需要催化剂也不需要强氧化剂，这表明可以预期它具有广泛的用途，特别是对于对路易斯酸，过渡金属或强氧化剂敏感的底物。
• N-(1-(SUBSTITUTED-PHENYL)ETHYL)-9H-PURIN-6-AMINES AS PI3K INHIBITORS
  申请人：Li Yun-Long

  公开号：US20120157430A1

  公开（公告）日：2012-06-21

  The present invention provides N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

  本发明提供了调节磷脂酰肌醇3-激酶（PI3Ks）活性并且在治疗与PI3Ks活性相关的疾病方面有用的N-(1-(取代苯基)乙基)-9H-嘌呤-6-胺衍生物，例如炎症性疾病、免疫性疾病、癌症和其他疾病。
• SUBSTITUTED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXYLIC ACIDS AND METHOD OF USE
  申请人：AbbVie S.à.r.l.

  公开号：US20170101406A1

  公开（公告）日：2017-04-13

  The present invention provides for compounds of formula (I) wherein R 1 , R 2 , R 3 , and R 4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

  本发明提供了式（I）的化合物 其中R 1 ，R 2 ，R 3 和R 4 具有规范中定义的任何值，以及其药学上可接受的盐，这些化合物在治疗由CFTR介导和调节的疾病和症状中是有用的，包括囊性纤维化、Sjögren综合征、胰腺功能不全、慢性阻塞性肺病和慢性阻塞性气道疾病。还提供了由一个或多个式（I）的化合物组成的药物组合物。
• SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20200039989A1

  公开（公告）日：2020-02-06

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

  这项发明属于药物化学领域。具体来说，该发明涉及一类新型小分子，具有6,5-杂环结构（例如，具有咪唑吡啶、咪唑吡嘧啶、咪唑吡嗪、咪唑吡啶嗪、咪唑三嗪、苯并咪唑、苯并三唑、苯并异嗪、嘌呤、吲唑、三唑三嗪、三唑吡啶嗪、三唑吡嘧啶、三唑吡嗪、三唑四嗪、三唑吡啶、吡唑吡嗪、吡唑吡嘧啶、吡唑吡啶嗪、吡唑三嗪、吡唑吡啶、异嗪吡嗪、异嗪吡嘧啶、异嗪吡啶嗪、异嗪三嗪、或异嗪吡啶结构），其作为DYRK1A、DYRK1B和Clk-1的抑制剂，以及它们作为治疗阿尔茨海默病、唐氏综合征、糖尿病、胶质母细胞瘤、自身免疫疾病、癌症（例如，胶质母细胞瘤、前列腺癌）、炎症性疾病（例如，气道炎症）和其他疾病的治疗药物的用途。